1 – 50 of 56
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The challenge of recruiting multimorbid older patients identified in a hospital database to a randomised controlled trial
(
- Contribution to journal › Article
- 2019
-
Mark
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE) : a modelling study
(
- Contribution to journal › Article
-
Mark
Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
(
- Contribution to journal › Article
-
Mark
Sex differences in predictors of mortality in patients with Alzheimer’s disease – A 20-year follow-up.
2019) 14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2019)(
- Contribution to conference › Abstract
-
Mark
Sex differences in predictors of cognitive and functional outcomes in patients with Alzheimer’s disease.
2019) 12th Clinical Trials on Alzheimer’s Disease Conference(
- Contribution to conference › Poster
- 2018
-
Mark
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia
(
- Contribution to journal › Article
- 2017
-
Mark
Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes
(
- Contribution to journal › Article
-
Mark
Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
(
- Contribution to journal › Article
-
Mark
Association between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals : A Longitudinal Descriptive Cohort Study
(
- Contribution to journal › Article
-
Mark
Cerebrovascular and amyloid pathology in predementia stages : The relationship with neurodegeneration and cognitive decline
(
- Contribution to journal › Article
-
Mark
Early- versus late-onset Alzheimer disease : Long-term functional outcomes, nursing home placement, and risk factors for rate of progression.
(
- Contribution to journal › Article
-
Mark
Early- versus late-onset Alzheimer's disease in clinical practice : Cognitive and global outcomes over 3 years
(
- Contribution to journal › Article
-
Mark
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers
(
- Contribution to journal › Article
-
Mark
The frequency and influence of dementia risk factors in prodromal Alzheimer's disease
(
- Contribution to journal › Article
- 2016
-
Mark
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
(
- Contribution to journal › Article
-
Mark
Early- versus Late-Onset Alzheimer’s Disease—Differences in Functional Impairment.
2016) 9th Clinical Trials Conference on Alzheimer’s Disease(
- Contribution to conference › Poster
- 2015
-
Mark
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
(
- Contribution to journal › Article
-
Mark
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
(
- Contribution to journal › Article
-
Mark
DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts.
(
- Contribution to journal › Article
-
Mark
The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey.
(
- Contribution to journal › Article
- 2014
-
Mark
Early- versus Late-onset Alzheimer’s Disease—3-year Outcomes of Cholinesterase Inhibitor Treatment in Routine Clinical Practice.
2014) 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster
- 2013
-
Mark
Mild versus Moderate Stage of Alzheimer’s Disease—Three-year Outcomes of Cholinesterase Inhibitor Therapy in a Routine Clinical Setting.
(
- Contribution to conference › Abstract
-
Mark
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
(
- Contribution to journal › Article
-
Mark
Living Alone in Alzheimer’s Disease—The Influence of Functional Impairment.
2013) 6th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster
-
Mark
Three-year outcome of rivastigmine treatment in Alzheimer's disease in a routine clinical setting.
2013) 11th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2013)(
- Contribution to conference › Poster
-
Mark
Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.
(
- Contribution to journal › Article
- 2012
-
Mark
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
(
- Contribution to journal › Article
-
Mark
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
(
- Contribution to journal › Article
-
Mark
Alzheimer’s disease with normal CSF biomarkers.
2012) 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
- 2011
-
Mark
Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Predictors of long-term cognitive outcome in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
The long-term cognitive outcomes of Alzheimer’s disease — influence of APOE genotype, NSAID therapy, and cholinesterase inhibitor treatment.
2011) 10th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2011)(
- Contribution to conference › Poster
- 2010
-
Mark
The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of A beta in different brain regions
(
- Contribution to journal › Article
-
Mark
CSF biomarkers predict a more malignant outcome in Alzheimer disease.
(
- Contribution to journal › Article
-
Mark
Plasma concentration of galantamine - influence of dose and body mass index in Alzheimer’s disease.
2010) 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
- 2009
-
Mark
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil
(
- Contribution to journal › Article
-
Mark
Long-term rivastigmine treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Cholinesterase Inhibitor Treated Naturalistic Alzheimer Patients.
2009) 9th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)(
- Contribution to conference › Poster
- 2008
-
Mark
Long-term treatment response, predictors and biochemical markers in Alzheimer’s disease.
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Predicting Long-Term Cognitive Outcome with New Regression Models in Donepezil-Treated Alzheimer Patients in a Naturalistic Setting.
(
- Contribution to journal › Article
- 2007
-
Mark
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Activities of daily living - Outcome during two years in galantamine treated Alzheimer patients
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Activities of Daily Living – Outcome During Three Years in Donepezil Treated Alzheimer Patients.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster
-
Mark
Three-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster